Persistence of Solifenacin Treatment in Overactive Bladder Patients in Real Life Practice: A 12-month, Prospective, Multicenter, Open-label, Observational Study.

Trial Profile

Persistence of Solifenacin Treatment in Overactive Bladder Patients in Real Life Practice: A 12-month, Prospective, Multicenter, Open-label, Observational Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Apr 2016

At a glance

  • Drugs Solifenacin (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 01 Apr 2016 Results (n=1018) published in the International Journal of Clinical Practice.
    • 11 Oct 2011 Actual end date Aug 2011 added as reported by ClinicalTrials.gov.
    • 11 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top